RealFeedApp Rose BioSolutions prioritizes patients over clients
David Enloe, CEO of Rose BioSolutions, argues that the traditional outsourcing model is obsolete for complex cell and gene therapies. He advocates for CDMOs to act as an extension of the sponsor's team, providing scientific leadership, regulatory expertise, and program management to ensure efficient clinical progress.
- Field
- business and funding
- What they did
- David Enloe, CEO of Rose BioSolutions, argues that the traditional outsourcing model in biopharma is becoming obsolete.
- Why it matters
- This approach could help sponsors and manufacturers build more effective partnerships where CDMOs act as an extension of the client's team rather than just vendors.
#cdmo#biopharma#cell therapy#gene therapy#regulatory expertise
